Farmaforum Partnering Day 2026

23 Sept 2026 | Madrid, Spain

Register
Register
Register

InvestmentUpdated on 25 August 2026

Pre-Series A

CEO at Microviable Therapeutics SL

Gijón, Spain

About

Microviable Therapeutics is a biotech company at preclinical stage developing novel biological medicines for oncology and infectious diseases. Our drugs are oral capsules containing naturally existing bacteria. These biological medicines are rationally designed to increase the efficacy of immunotherapy in solid tumors, and to ablate MDR-pathogenic bacteria in infectious diseases.

Microviable has three assets under development. Our lead candidate, MVT-201 (IP granted 2026), has finalized preclinical development, is currently under CMC aiming to start clinical trials in 2027 for CRC.

Until now, Microviable has secure 6M € funding combining competitive grants and equity. We are currently looking to raise a 3M € pre-series A funding to support our first-in-human clinical trial in colorectal cancer, and to advance the preclinical development of the other two assets.

Organisation

Similar opportunities